Deerfield, Ill. – May 12, 2020 – For the fifth straight year, patient groups ranked Lundbeck US, an affiliate of the global pharmaceutical company H. Lundbeck A/S, #1 in corporate reputation. According to the new PatientView Corporate Reputation of Pharma, USA Edition, Lundbeck ranked 1st overall among leading pharmaceutical companies, as judged by U.S.-based patient groups that work or partner with the company.
“At Lundbeck, patient-centricity defines our culture, and we are honored that our patient-group partners recognize our authentic commitment,” said Peter Anastasiou, executive vice president and head of Lundbeck North America. “As the only global biopharmaceutical company solely focused on brain diseases, we are deeply committed to understanding the complex needs of our patient communities. Our patient-group partners are critical to our ability to deliver therapies and programs that will be most meaningful to people impacted by brain diseases, and we are grateful for their trust and ongoing collaboration.”
The PatientView report, which is based on a survey of 186 U.S. patient groups, compiles feedback on the performance of pharmaceutical companies on key indicators of corporate reputation. In addition to awarding the overall #1 ranking, patient groups that have worked or partnered with Lundbeck also ranked the company #1 in these nine individual reputational categories:
In 2019, Lundbeck partnered with 33 different patient groups, and the company’s approximately 900 U.S. employees participated in nearly 400 patient advocacy events across the country. “Colleagues at every level and within every department of our organization embrace the opportunity to connect with our patient communities,” Anastasiou said. “These regular touchpoints allow us to hear directly from the people we serve and grants us better understanding of the needs of patients and their care partners.”
Novel patient-group collaborations
Lundbeck also regularly engages with patient groups in more organized ways, convening representatives of patient communities to gain insights into gaps in treatment, educational resources and community support. Highlights from the past year include:
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Our approximately 6,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy.
In the U.S., Lundbeck employs approximately 900 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities.
Lundbeck Media Contact:
Associate Director, Corporate Communications